# Denis Moro‐Sibilot
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/denis-moro-sibilot/
## Facts
| Field | Value |
| --- | --- |
| Citations | 33,516 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 70 |
| i10-index | 208 |
| Last Known Institution | Centre Hospitalier Universitaire de Grenoble |
| OpenAlex ID | https://openalex.org/A5030455508 |
| ORCID iD | 0000-0001-6776-8610 |
| Works | 628 |
## Researcher papers
Showing 12 of 27.
- [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/)
- [Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study](https://scholariq.org/papers/first-line-ceritinib-versus-platinum-based-chemotherapy-in-advanced-alk/)
- [Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/bevacizumab-for-newly-diagnosed-pleural-mesothelioma-in-the-mesothelioma-avastin/)
- [Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-and-chemotherapy-in-non-small-cell-lung-cancer/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer](https://scholariq.org/papers/intestinal-akkermansia-muciniphila-predicts-clinical-response-to-pd-1-blockade/)
- [Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives](https://scholariq.org/papers/lung-cancer-that-harbors-an-i-her2-i-mutation-epidemiologic-characteristics-and/)
- [Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers](https://scholariq.org/papers/ectopic-activation-of-germline-and-placental-genes-identifies-aggressive/)
- [COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study](https://scholariq.org/papers/covid-19-in-patients-with-thoracic-malignancies-teravolt-first-results-of-an/)
- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
## Researcher university
- [Centre Hospitalier Universitaire de Grenoble](https://scholariq.org/institutions/centre-hospitalier-universitaire-de-grenoble/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.